{
  "ticker": "CC5",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968948",
  "id": "02968948",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0935",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrxdypxrncjw.pdf",
  "summary": "- **APAS\u00ae Independence sale** to Novo Nordisk for evaluation in their European operations.  \n- **Evaluation purpose**: Assess suitability of APAS\u00ae technology for pharmaceutical environmental monitoring (90mm and 55mm plate analysis).  \n- **Sales strategy progress**: Five multinational pharma customers secured (including Novo Nordisk), representing potential sales opportunity of **60\u201380 APAS\u00ae units**.  \n- **Future outlook**: More evaluations/sales expected with large pharma customers in FY2026.  \n\n*No capital-raising, financial data, or material valuation impacts disclosed.*",
  "usage": {
    "prompt_tokens": 1263,
    "completion_tokens": 116,
    "total_tokens": 1379,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T23:46:22.083917"
}